| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443871 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
A sensitive population of patients more likely to benefit from oxaliplatin reintroduction is defined by the efficacy of induction therapy followed by an OFI of at least 6Â months between two periods of FOLFOX therapy. OFI of <6Â months identifies a subgroup of partially-resistant patients who can still benefit from oxaliplatin reintroduction.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Benoist Chibaudel, Christophe Tournigand, Franck Bonnetain, Frédérique Maindrault-Goebel, Gérard Lledo, Thierry André, Annette K. Larsen, Leila Bengrine-Lefevre, Christophe Louvet, Aimery de Gramont,